The primary endpoint for this trial is the improvement in COVID-19 between the placebo and E4 groups measured by the percentage of patients recovered at Day 28. Recovery will be defined as reaching a score of ≤3 on the WHO (0-10) scale.

The primary endpoint for this trial is the improvement in COVID-19 between the placebo and E4 groups measured by the percentage of patients recovered at Day 28. Recovery will be defined as reaching a score of ≤3 on the WHO (0-10) scale.